Pirtobrutinib Approval Adds Effective Third-Line Option for Previously Treated CLL/SLL.
- Published in:
- 2024
- By:
- Publication type:
- Interview
Works matching IS 23745347 AND DT 2024 AND VI 25 AND IP 3
Results: 14
1
2
Frontline Camrelizumab/ Rivoceranib Combination Shows Promise in Unresectable HCC.
- Published in:
- OncologyLive, 2024, v. 25, n. 3, p. 44
- By:
- Publication type:
- Article
3
Neoadjuvant SBRT Plus Cemiplimab Results in Pathologic Responses in Resectable HCC.
- Published in:
- OncologyLive, 2024, v. 25, n. 3, p. 61
- By:
- Publication type:
- Article
4
4 Health Care Industry Trends for 2024.
- Published in:
- OncologyLive, 2024, v. 25, n. 3, p. 49
- By:
- Publication type:
- Article
5
Early-Phase Clinical Research Center Poised to Provide New Benefits in Hawaii and Beyond.
- Published in:
- OncologyLive, 2024, v. 25, n. 3, p. 48
- By:
- Publication type:
- Article
6
POSEIDON Trial Update Confirms OS Benefit of Tremelimumab Plus Durvalumab and Chemotherapy in Advanced NSCLC.
- Published in:
- OncologyLive, 2024, v. 25, n. 3, p. 63
- By:
- Publication type:
- Article
7
Enasidenib Plus Venetoclax Yields High Response Rates Targeting IDH2 Mutations in R/R AML.
- Published in:
- OncologyLive, 2024, v. 25, n. 3, p. 39
- By:
- Publication type:
- Article
8
Gynecologic Oncologists Explore Treatment Options in LGSOC, Look Toward Promising Future.
- Published in:
- OncologyLive, 2024, v. 25, n. 3, p. 59
- By:
- Publication type:
- Article
9
Lonial Spotlights CAR T-Cell and Off-the-Shelf Treatments in Multiple Myeloma.
- Published in:
- OncologyLive, 2024, v. 25, n. 3, p. 32
- By:
- Publication type:
- Article
10
The Importance of Lung Cancer Screening in Individuals Exposed to the World Trade Center Disaster.
- Published in:
- OncologyLive, 2024, v. 25, n. 3, p. 46
- By:
- Publication type:
- Article
11
A Roundup of 2023 FDA Oncology Approvals and Withdrawals.
- Published in:
- OncologyLive, 2024, v. 25, n. 3, p. 8
- By:
- Publication type:
- Article
12
Actionable Molecular Findings: Increasingly Clinically Relevant but Also Increasingly Complex.
- Published in:
- 2024
- By:
- Publication type:
- Editorial
13
SABCS 2023 Findings Build on Positive Momentum in HER2+ Breast Cancer.
- Published in:
- OncologyLive, 2024, v. 25, n. 3, p. 24
- By:
- Publication type:
- Article
14
2023 FDA Approvals Set Accelerated Pace for 2024.
- Published in:
- OncologyLive, 2024, v. 25, n. 3, p. 4
- By:
- Publication type:
- Article